undamentalytics Newsletter
Sign in

Globus Medical Inc (GMED) stock

Add to watchlist

Add holding +

NYSE: GMED NYSE Health Care Equipment Next results ~November 5, 2026

B Fundamentals grade

Globus Medical Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$110

Cash-flow model

Base case. Range ~$82–$140 across our lower- and higher-growth cases (8%–18% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 36% above it.

Price used: $79.46, November 2, 2026

Globus Medical Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Globus Medical files

Where Globus Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $3.14bn, up 19.7% on a year earlier, slower than 23.5% a quarter earlier. That growth ranks 181 of 931 among all the companies we cover. Free-cash-flow margin rose to 24.0% from 20.1% a year earlier. Operating margin widened to 20.3% from 10.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $118 a share, against a share price of $78.29. At that price, our model says the market is pricing in about 5.6% a year of cash-flow growth for five years, slower than the 26.8% a year revenue growth it has delivered.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Globus Medical Inc's trailing-twelve-month revenue grew 19.7% year on year, with a free-cash-flow margin of 24.0%. Where it stands out: free-cash-flow margin of 24.0% ranks 8 of 128 health care equipment companies we cover. Where it lags: days sales outstanding of 80 days ranks 96 of 118 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$110 per share in the base case (~$82–$140 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Gross margin expanding: TTM gross margin reached 68.5%, up 5.8pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $79.46 is 36% below our value per share of $110.
  • Fast growth. Revenue grew 19.7% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 9.6 points on a year ago.
  • Strong cash generation. 24.0% of revenue turned into free cash flow, against a median of -3.4% for health care equipment companies we cover.
  • Shrinking share count. Diluted shares fell 1.4% in a year, so each share owns more of the business.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 49% and a beta of 0.7 against the S&P 500.
  • Insiders selling. 7 insiders sold $18M of stock over the past 365 days and none bought (39% under pre-set trading plans).
  • Growth easing. The growth rate is 3.8 points lower than a quarter earlier.
  • Below peers: days sales outstanding. Days sales outstanding of 80 days ranks 96 of 118 health care equipment companies we cover (median 57 days).
  • Short interest rising. Shares sold short rose 21% in a month to 7.4% of tradable shares.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$1.34 against an average estimate of $1.10: beat by 21.9%
Revenue
$790m, up 5.9% on a year earlier
Share reaction
+2.2% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
revenue $3.18bn to $3.22bn (full-year 2026); non-GAAP fully diluted EPS $4.95 to $5.05 (full-year 2026)
Next report
November 5, 2026; average EPS estimate $1.20

Globus Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week-2.9%
  • 1 month+5.1%
  • This year-9.0%
  • 1 year+31.6%
  • 5 years+1.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.1B
Operating margin
20.3%
Net margin
17.0%
EPS (TTM, diluted)
$3.91

Growth

Revenue growth
+19.7%
Change in growth rate
−3.8 pts
Share count change
−1.4%

Cash

Free cash flow (TTM)
$756M
FCF margin
24.0%
Stock pay % of revenue
1.6%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Results
  4. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Globus Medical Inc valuation models and calculator

What the price is pricing in

The share price implies about 5.5% a year of cash-flow growth for five years.That is slower than the 26.8% a year revenue growth Globus Medical has delivered.

  • Priced in5.5%
  • Last 12 months19.7%
  • 3 years a year42.1%
  • 5 years a year26.8%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($79.25, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$110
Price used
$79.25close November 3, 2026
Implied change
▲ +36%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Globus Medical Inc's free cash flow after stock-based pay with after-tax interest added back ($507M, FY2026 Q2 TTM), growing 6.9% and 10.6% in the next two years (forecasts, guidance and its record), then back to 13% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$82–~$140 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Globus Medical Inc's free cash flow after stock-based pay ( $507M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Globus Medical Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$110 ~$82–$140 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$89 ~$78–$140 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$34 ~$22–$55 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$34 ~$29–$42 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$75 ~$34–$110 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Globus Medical Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −23%
  • Revenue growth 5 points higher ▲ +30%
  • Free-cash-flow margin 1 point lower ▼ −4%
  • Last year's free-cash-flow margin change, if it persists ▲ +19%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $58$77$102$135$179$235
8.5% $45$59$77$101$132$172
10% $38$48$62$81$104$134

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$27.82$24.81$41.10$43.28$58.88$65.22$72.20$74.27$53.29$82.71$87.31$79.46
Market value$2.7bn$2.4bn$4.0bn$4.4bn$6.0bn$6.6bn$7.5bn$7.6bn$6.1bn$11.4bn$12.0bn$10.9bn
+ Net debt (− = net cash)−$58m−$67m−$119m−$140m−$195m−$239m−$193m−$150m−$50m−$784m−$526m−$508m
Enterprise value$2.6bn$2.3bn$3.9bn$4.2bn$5.8bn$6.3bn$7.3bn$7.5bn$6.1bn$10.6bn$11.4bn$10.4bn
Multiples
Price / sales 4.9x4.2x6.3x6.2x7.6x8.3x7.8x7.5x3.9x4.5x4.1x3.5x
Price / earnings 23.7x22.9x37.5x28.0x38.7x64.4x50.1x40.1x49.7x110.7x22.2x20.3x
Price / free cash flow 36.5x22.4x37.3x36.0x59.3x48.7x34.1x73.0x37.0x28.1x20.3x14.4x
EV / EBITDA 13.3x12.1x19.1x20.1x25.9x36.4x30.1x25.2x21.7x25.3x15.1x12.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

71 /100

Strong moat

How hard Globus Medical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 19 / 20

    Cash operating profit has been a median 14.6% of total assets over 10 years.

  • Pricing power 16 / 20

    Gross margin has been a median 74.3%, moving by 5.8 percentage points (standard deviation) across 10 years.

  • Durability 8 / 20

    Operating margin has been a median 19.7%; its worst year was 3.0%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 16.3% of revenue.

  • Discipline 9 / 20

    The diluted share count rose 33.5% over five years; stock-based pay has been a median 2.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $792m and EPS of $1.20 (range $1.13 to $1.26) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $5.00 +26% $3.2bn +9%
Next $5.39 +8% $3.4bn +6%

Next year's EPS estimate has moved +4.7% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.4% on 90 days ago. In the last 30 days, 13 analysts raised Globus Medical Inc's forecast and 0 cut it.

Consensus EPS forecast Globus Medical Inc, last 90 days
$4.60 $4.80 $5.00 $5.20 $5.40 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $4.74 Current fiscal year, 60 days ago: $4.98 Current fiscal year, 30 days ago: $5.00 Current fiscal year, 7 days ago: $5.00 Current fiscal year, Now: $5.00 $5.00 Next fiscal year, 90 days ago: $5.15 Next fiscal year, 60 days ago: $5.36 Next fiscal year, 30 days ago: $5.40 Next fiscal year, 7 days ago: $5.39 Next fiscal year, Now: $5.39 $5.39

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $4.74$5.15
60 days ago $4.98$5.36
30 days ago $5.00$5.40
7 days ago $5.00$5.39
Now $5.00$5.39

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.10 $1.34 +21.9%
Mar 2026 $0.92 $1.12 +21.7%
Dec 2025 $1.15 $1.28 +11.0%
Sept 2025 $0.78 $1.18 +51.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • revenue full-year 2026 $3.18bn to $3.22bn Maintained
    “The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80.” source
  • non-GAAP fully diluted EPS full-year 2026 $4.95 to $5.05 Non-GAAP Raised
    “The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Globus Medical Inc's revenue by +6.9% next year and +10.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+4.9%, weight 56%) , management guidance (+4.9%, weight 19%) and the company's own record (+13.0%, weight 25%) . How the weights are set.

Analyst recommendations

14 analysts, Oct 2026
Buy1071%
Hold429%
Sell00%

Monthly trend

  1. Oct 202637414
  2. Sep 202637515
  3. Aug 202637515
  4. Jul 202637515

Counts of recommendations published by analysts covering Globus Medical Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.4%
of tradable shares
Days to cover
5.17
at average volume
Short interest, 1 month
+21%
to October 15, 2026
Held by institutions
94%
of shares
Held by insiders
0.6%
of shares
Employees
6,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +31.6%

$60.39 on October 31, 2025 to $79.46

ThenNowEffect
Revenue (last 12 months) $2.6bn $3.1bn +19.7%
Net margin 13.6% 17.0% +25.4%
P/E multiple 23.5x 20.3x −13.6%
Share count 139m 137m +1.4%

Biggest factor: net margin.

Last 3 years +69.1%

$46.99 on November 3, 2023 to $79.46

ThenNowEffect
Revenue (last 12 months) $1.1bn $3.1bn +186.7%
Net margin 18.6% 17.0% −8.6%
P/E multiple 23.4x 20.3x −13.3%
Share count 102m 137m −25.6%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GMED+11%+3%−28%+55%+6%−9%
Industry peers (median)−9%−37%−8%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GMED58%75%42%58%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GMED−26%−35%−45%−12%−44%−24%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 48% from September 8, 2021 to November 13, 2023. Getting back needed a 92% gain, reached on November 21, 2024, 374 days after the low.

Price behaviour

52-week range
$61.20 – $96.82
From 52-week high
−17.9%
vs 50-day average
+2.6%
vs 200-day average
−4.8%
Volatility (1 year)
49%
Beta vs S&P 500
0.69

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±9.8%
After a week
5 up, 7 down
typical move ±10.2%
After a month
6 up, 6 down
typical move ±11.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +2.2% +0.5% +6.7% −2.8%
May 7, 2026 −12.6% +0.5% −13.5% −12.2%
February 24, 2026 +3.0% +1.6% −1.8% −6.5%
January 7, 2026 +1.4% −0.3% −0.9% −5.9%
November 6, 2025 +36.4% −1.0% +36.5% +44.7%
August 7, 2025 +11.0% +0.7% +13.6% +12.7%
July 21, 2025 −5.9% +0.2% −3.6% +8.6%
May 8, 2025 −21.9% +0.6% −19.1% −15.6%
February 20, 2025 −4.5% −2.1% −6.4% −12.5%
January 8, 2025 +4.3% −1.4% +8.4% +4.7%
November 5, 2024 +10.7% +3.7% +11.6% +11.2%
August 6, 2024 +4.0% +0.2% −0.7% +4.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Globus Medical Inc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Globus Medical Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Globus Medical Inc
$1B $1.5B $2B $2.5B $3B $3.5B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.2B Revenue (TTM), FY23 Q4: $1.6B Revenue (TTM), FY24 Q1: $1.9B Revenue (TTM), FY24 Q2: $2.2B Revenue (TTM), FY24 Q3: $2.5B Revenue (TTM), FY24 Q4: $2.5B Revenue (TTM), FY25 Q1: $2.5B Revenue (TTM), FY25 Q2: $2.6B Revenue (TTM), FY25 Q3: $2.8B Revenue (TTM), FY25 Q4: $2.9B Revenue (TTM), FY26 Q1: $3.1B Revenue (TTM), FY26 Q2: $3.1B $3.1B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.2B
FY23 Q4 $1.6B
FY24 Q1 $1.9B
FY24 Q2 $2.2B
FY24 Q3 $2.5B
FY24 Q4 $2.5B
FY25 Q1 $2.5B
FY25 Q2 $2.6B
FY25 Q3 $2.8B
FY25 Q4 $2.9B
FY26 Q1 $3.1B
FY26 Q2 $3.1B
Revenue growth, TTM YoY Globus Medical Inc
0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 22.8% Revenue growth, TTM YoY, FY23 Q4: 53.3% Revenue growth, TTM YoY, FY24 Q1: 77.6% Revenue growth, TTM YoY, FY24 Q2: 103.9% Revenue growth, TTM YoY, FY24 Q3: 102.1% Revenue growth, TTM YoY, FY24 Q4: 60.6% Revenue growth, TTM YoY, FY25 Q1: 32.3% Revenue growth, TTM YoY, FY25 Q2: 17.4% Revenue growth, TTM YoY, FY25 Q3: 11.7% Revenue growth, TTM YoY, FY25 Q4: 16.7% Revenue growth, TTM YoY, FY26 Q1: 23.5% Revenue growth, TTM YoY, FY26 Q2: 19.7% 19.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 22.8%
FY23 Q4 53.3%
FY24 Q1 77.6%
FY24 Q2 103.9%
FY24 Q3 102.1%
FY24 Q4 60.6%
FY25 Q1 32.3%
FY25 Q2 17.4%
FY25 Q3 11.7%
FY25 Q4 16.7%
FY26 Q1 23.5%
FY26 Q2 19.7%
Operating margin (TTM) Globus Medical Inc
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 14.4% Operating margin (TTM), FY23 Q4: 8.5% Operating margin (TTM), FY24 Q1: 4.5% Operating margin (TTM), FY24 Q2: 3.0% Operating margin (TTM), FY24 Q3: 4.7% Operating margin (TTM), FY24 Q4: 6.6% Operating margin (TTM), FY25 Q1: 10.2% Operating margin (TTM), FY25 Q2: 10.7% Operating margin (TTM), FY25 Q3: 13.4% Operating margin (TTM), FY25 Q4: 16.3% Operating margin (TTM), FY26 Q1: 17.2% Operating margin (TTM), FY26 Q2: 20.3% 20.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 14.4%
FY23 Q4 8.5%
FY24 Q1 4.5%
FY24 Q2 3.0%
FY24 Q3 4.7%
FY24 Q4 6.6%
FY25 Q1 10.2%
FY25 Q2 10.7%
FY25 Q3 13.4%
FY25 Q4 16.3%
FY26 Q1 17.2%
FY26 Q2 20.3%
FCF margin (TTM) Globus Medical Inc
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 10.5% FCF margin (TTM), FY23 Q4: 10.5% FCF margin (TTM), FY24 Q1: 8.0% FCF margin (TTM), FY24 Q2: 7.2% FCF margin (TTM), FY24 Q3: 11.9% FCF margin (TTM), FY24 Q4: 16.1% FCF margin (TTM), FY25 Q1: 20.8% FCF margin (TTM), FY25 Q2: 20.1% FCF margin (TTM), FY25 Q3: 20.9% FCF margin (TTM), FY25 Q4: 20.0% FCF margin (TTM), FY26 Q1: 19.7% FCF margin (TTM), FY26 Q2: 24.0% 24.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 10.5%
FY23 Q4 10.5%
FY24 Q1 8.0%
FY24 Q2 7.2%
FY24 Q3 11.9%
FY24 Q4 16.1%
FY25 Q1 20.8%
FY25 Q2 20.1%
FY25 Q3 20.9%
FY25 Q4 20.0%
FY26 Q1 19.7%
FY26 Q2 24.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Globus Medical took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $2.9B
  2. Other income $125M · 4.3%
  3. Cost of revenue $958M · 32.6%
  4. Gross profit $2B · 67.4%
  5. Research and development $147M · 5.0%
  6. Selling, general and admin $1.2B · 40.1%
  7. Other operating costs $176M · 6.0%
  8. Operating income $480M · 16.3%
  9. Income tax $67.2M · 2.3%
  10. Net income $538M · 18.3%

Shares of revenue. Source: Globus Medical's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 288 331 386 434 474 545 564 636 713 785 789 958 1,023 1,568 2,519 2,939 3,145
Gross profit 234 263 311 334 364 412 429 486 554 605 572 719 759 1,020 1,484 1,981 2,156
EBITDA 103 114 133 121 160 196 193 204 211 225 174 242 296 279 419 757 860
Operating income 88 97 115 102 138 172 154 162 169 172 111 172 228 133 166 480 640
Net income 54 61 74 69 92 113 104 107 156 155 102 149 190 123 103 538 535
Diluted EPS $0.60 $0.67 $0.80 $0.73 $0.97 $1.17 $1.08 $1.10 $1.54 $1.52 $1.01 $1.44 $1.85 $1.07 $0.75 $3.92 $3.91
Growth (year on year)
Revenue — +15.0% +16.4% +12.6% +9.2% +14.8% +3.5% +12.8% +12.1% +10.2% +0.5% +21.4% +6.8% +53.3% +60.6% +16.7% +19.7%
EBITDA — +11.1% +16.3% −8.9% +32.3% +22.6% −1.7% +5.7% +3.5% +6.5% −22.4% +38.7% +22.5% −5.9% +50.5% +80.4% +74.8%
Operating income — +11.0% +17.9% −11.4% +36.1% +24.5% −10.5% +5.0% +4.6% +1.6% −35.2% +54.3% +32.6% −41.6% +24.7% +189.1% +127.2%
Net income — +11.6% +21.5% −7.1% +34.8% +21.9% −7.5% +2.9% +45.8% −0.8% −34.1% +45.9% +27.5% −35.4% −16.2% +422.3% +50.1%
Diluted EPS — +11.7% +19.4% −8.8% +32.9% +20.6% −7.7% +1.9% +40.0% −1.3% −33.6% +42.6% +28.5% −42.2% −29.9% +422.7% +52.3%
Margins
Gross margin 81.3% 79.2% 80.5% 76.9% 76.6% 75.7% 76.1% 76.3% 77.6% 77.1% 72.4% 75.0% 74.2% 65.1% 58.9% 67.4% 68.5%
EBITDA margin 35.7% 34.5% 34.4% 27.9% 33.8% 36.0% 34.2% 32.1% 29.6% 28.6% 22.1% 25.2% 29.0% 17.8% 16.6% 25.7% 27.4%
Operating margin 30.4% 29.4% 29.7% 23.4% 29.2% 31.6% 27.3% 25.4% 23.7% 21.9% 14.1% 17.9% 22.3% 8.5% 6.6% 16.3% 20.3%
Net margin 18.9% 18.3% 19.1% 15.8% 19.5% 20.7% 18.5% 16.9% 21.9% 19.8% 13.0% 15.6% 18.6% 7.8% 4.1% 18.3% 17.0%
Free-cash-flow margin 20.5% 16.3% 13.4% 16.1% 11.5% 13.4% 19.0% 16.9% 17.1% 12.9% 17.1% 22.9% 10.2% 10.5% 16.1% 20.0% 24.0%
Cash flow
Cash from operations 71 76 77 93 79 124 148 159 182 172 199 276 178 243 521 753 910
Capital spending 12 22 25 24 25 51 41 51 60 71 64 57 74 78 115 165 155
Free cash flow 59 54 52 70 54 73 107 108 122 101 135 219 104 165 405 589 756
Stock-based pay 4 3 5 5 7 10 11 15 22 26 27 31 33 53 54 50 49
Free cash flow after stock pay 55 51 47 65 47 64 96 93 100 75 108 189 72 112 351 539 707
Balance sheet
Cash 112 143 212 90 82 58 67 119 140 195 239 193 150 467 784 526 508
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 417 — 0 0
Net debt (negative = net cash) −112 −143 −212 −90 −82 −58 −67 −119 −140 −195 −239 −193 −150 −50 −784 −526 −508
Diluted shares 91m 90m 92m 94m 95m 96m 96m 98m 101m 102m 101m 104m 103m 115m 138m 137m 137m
Returned to shareholders
Buybacks 0 10 0 0 — — — — — — 105 — 144 226 86 300 221
Total returned 0 10 0 0 — — — — — — 105 — 144 226 86 300 221

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $5.5bn
Short-term assets $2.2bnLonger-term assets $3.3bn
What it owes, and who funded it · $5.5bn
Short-term liabilities $479mLonger-term liabilities $240mShareholders' equity $4.8bn
  • Short-term assets cover short-term liabilities $2.2bn of assets due within a year against $479m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.2bn short-term assets against $240m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Globus Medical Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$221M
Returned to shareholders
29%
of free cash flow
Buybacks, last 3 fiscal years
$612M
Diluted share count
−1.4%
year over year
Total shareholder yield
2.0%
dividends 0.0% + buybacks 2.0% of market value
R&D spending
4.7%
of revenue
Sales & admin spending
38.7%
of revenue
Days sales outstanding
80 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated GMED PODD RVTY QDEL ENOV TFX Median
Revenue, last 12 months $3.1bn $3.1bn $2.9bn $2.7bn $2.3bn $2.3bn $99m
Revenue growth, last 12 months 19.7% 29.4% 4.1% −2.5% 4.9% 30.7% 9.2%
Revenue growth, 3-year average 42.1% 27.7% 0.9% −5.4% 12.2% −8.0% 13.5%
Revenue growth, latest quarter 5.9% 23.5% 1.3% 2.8% 3.2% 28.9% 10.2%
Gross margin 68.5% 71.1% 60.1% — 61.1% 54.9% 61.2%
Operating margin 20.3% 16.9% 12.3% −30.8% −45.1% 2.0% −8.5%
Operating margin, 3-year average 11.4% 16.2% 12.0% −34.4% −28.5% 5.7% −17.9%
Net margin 17.0% 12.3% 8.2% −39.2% −48.0% −45.8% −12.0%
Cash from operations / revenue 28.9% 16.7% 21.6% −2.1% 11.8% 10.8% −1.9%
Free-cash-flow margin 24.0% 9.0% 19.2% −7.9% 2.8% 7.5% −3.9%
Free-cash-flow margin, 3-year average 17.1% 11.6% 17.1% −4.5% −0.2% 7.7% −7.0%
Stock pay / revenue 1.6% 2.6% 0.3% 1.7% 1.5% 1.1% 6.1%
Change in share count −1.4% −3.6% −6.2% 0.9% 1.7% −4.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 19.7% 9.1% 40 of 129
Change in growth rate Growth -3.8pp -0.6pp 96 of 129
Gross margin Profitability 68.5% 61.9% 45 of 123
Operating margin Profitability 20.3% -8.3% 12 of 132
Net margin Profitability 17.0% -12.0% 13 of 133
Free-cash-flow margin Cash generation 24.0% -3.4% 8 of 128
Stock pay as % of revenue Cash generation 1.6% 6.1% 24 of 123
Change in share count Balance sheet -1.4% 3.3% 22 of 115
Days sales outstanding Balance sheet 80 days 57 days 96 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Musculoskeletal Solutions $2.8B 95.2% ▲ 18.3%
Enabling Technologies $141M 4.8% ▼ 8.4%
Geography
Region Revenue Share YoY
United States $2.4B 80.6% ▲ 18.4%
Outside the US $571M 19.4% ▲ 10.0%

From Globus Medical Inc's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$9.5B
Institutions reporting
596
Shares held vs prior quarter
▲ 9.0%
Positions opened / closed
71 / 86

Top buyers and sellers, Q2 2026: 323 institutions bought and 267 sold ; the biggest buyer was Kayne Anderson Rudnick Investment Management LLC (+4.3M shares) and the biggest seller Citadel Advisors LLC (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $854M 10.8M 9.0% ▲ 2.9%
Jupiter Topco LLC $648M 8.2M 6.8% —
Vanguard Capital Management LLC $404M 5.1M 4.3% ▲ 1.5%
Vanguard Portfolio Management LLC $395M 5.0M 4.2% ▲ 2.4%
Invesco Ltd. $341M 4.3M 3.6% ▼ 0.2%
Kayne Anderson Rudnick Investment Management LLC $338M 4.3M 3.6% New
State Street Corp $294M 3.7M 3.1% ▲ 3.4%
Sculptor Capital LP $237M 3.0M 2.5% ▼ 1.9%
Jpmorgan Chase & Co $231M 2.7M 2.4% ▲ 5.7%
Alliancebernstein L.P. $205M 2.4M 2.2% ▲ 36.0%
Bank Of Montreal $192M 2.4M 2.0% ▲ 5.1%
Dimensional Fund Advisors LP $187M 2.4M 2.0% ▲ 33.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Globus Medical Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $17.5M 14 trades by 7 insiders · 39% under pre-set plans
Net ▼ $17.5M net selling
Insider Date Trade Shares Price Value
Tobin James R Director September 15, 2026 Sell 30,000 $74.58 $2.2M
Zarrilli Stephen T Director August 18, 2026 Sell 25,000 $87.04 $2.2M
Davidar David D Director June 5, 2026 Sell 25,000 $80.76 $2M
Huller Kelly EVP, GC, Corporate Secretary February 25, 2026 Sell pre-set plan 20,000 $94.50 $1.9M
Huller Kelly EVP, GC, Corporate Secretary February 12, 2026 Sell pre-set plan 10,000 $87.67 $876,700
Norwalk Leslie V Director January 8, 2026 Sell pre-set plan 2,000 $101.10 $202,200
Kline Kyle Senior Vice President, CFO January 8, 2026 Sell pre-set plan 3,594 $101.10 $363,353
Norwalk Leslie V Director December 12, 2025 Sell pre-set plan 4,000 $88.85 $355,400
Kline Kyle Senior Vice President, CFO December 1, 2025 Sell pre-set plan 18,542 $90.00 $1.7M
Huller Kelly SVP, GC, Corporate Secretary November 25, 2025 Sell pre-set plan 7,500 $90.00 $675,000
Davidar David D Director November 12, 2025 Sell 25,000 $86.00 $2.1M
Zarrilli Stephen T Director November 11, 2025 Sell 25,000 $84.29 $2.1M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 21 trades and filings

In the last 12 months, 1 member of Congress disclosed 3 purchases and 0 sales of Globus Medical Inc shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded September 3, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $15,001 - $50,000, traded August 19, 2026, filed September 10, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded March 3, 2026, filed April 7, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 19, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 24, 2026
  • January 7, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Globus Medical Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Globus Medical Inc in brief

What does Globus Medical Inc do?
Globus Medical Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Globus Medical Inc's stock ticker?
Globus Medical Inc trades under the ticker GMED on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Globus Medical Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Globus Medical Inc reported revenue of $3.1B, 19.7% higher than a year earlier, according to its SEC filings.
What is Globus Medical Inc's free cash flow?
Globus Medical Inc's free-cash-flow margin is 24.0% of revenue over the trailing twelve months, ranking 8 of the 128 health care equipment companies we cover.
What is Globus Medical Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Globus Medical Inc's free cash flow after stock-based pay gives ~$110 per share in the base case, and ~$82–$140 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Globus Medical Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Jupiter Topco LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Globus Medical Inc buying back stock, and does it pay a dividend?
Globus Medical Inc spent $221M on share repurchases over the trailing twelve months, and its diluted share count fell 1.4% over the year.
What is Globus Medical Inc's market cap?
On November 2, 2026, Globus Medical Inc's market capitalisation was about $10.9B, with a price-to-earnings ratio of 20.3 and net debt of -$508M. Market figures come from third-party market data and may be delayed.
Who are Globus Medical Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Globus Medical Inc are Insulet Corporation, Revvity, Quidelortho Corp, Enovis Corp and Teleflex Inc. The side-by-side comparison below sets their revenue, margins and growth against Globus Medical Inc's.
Are insiders buying or selling Globus Medical Inc stock?
Over the last 12 months, Globus Medical Inc's directors and officers reported 0 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Globus Medical Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Globus Medical Inc announces its own schedule.